Iproniazid

Iproniazid
Clinical data
Trade namesMarsilid, others
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Bioavailability1
Identifiers
  • N-isopropylisonicotinohydrazide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.199 Edit this at Wikidata
Chemical and physical data
FormulaC9H13N3O
Molar mass179.223 g·mol−1
3D model (JSmol)
Density1.084 g/cm3
Boiling point265.9 °C (510.6 °F)
  • O=C(NNC(C)C)c1ccncc1
  • InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13) checkY
  • Key:NYMGNSNKLVNMIA-UHFFFAOYSA-N checkY
  (verify)

Iproniazid (Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It is a xenobiotic that was originally designed to treat tuberculosis, but was later most prominently used as an antidepressant drug. However, it was withdrawn from the market because of its hepatotoxicity.[3][4] The medical use of iproniazid was discontinued in most of the world in the 1960s, but remained in use in France until its discontinuation in 2015.

  1. ^ Maxwell RA, Eckhardt SB (1990). "Iproniazid". Drug Discovery. Humana Press. pp. 143–154. ISBN 9780896031807.
  2. ^ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical Pharmacology. 35 (8): 1381–1387. doi:10.1016/0006-2952(86)90285-6. PMID 2870717.
  3. ^ Timbrell J (2008). Taylor & Francis Group. pp. 324–326. doi:10.3109/9781420007084. ISBN 978-0-8493-7302-2.
  4. ^ Henn F, Sartorius N, Helmchen H, Lauter H, eds. (2013-11-11). Contemporary Psychiatry. Springer Science & Business Media. p. 109. ISBN 9783642595196.